Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

BACKGROUND: Advanced melanoma is characterized by a pronounced resistance to therapy leading to a limited patient survival of ~6 - 9 months. Here, we report on a novel bifunctional therapeutic fusion protein, designated anti-MCSP:TRAIL, that is comprised of a melanoma-associated chondroitin sulfate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: de Bruyn, Marco, Rybczynska, Anna A, Wei, Yunwei, Schwenkert, Michael, Fey, Georg H, Dierckx, Rudi AJO, van Waarde, Aren, Helfrich, Wijnand, Bremer, Edwin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2010
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3000402/
https://ncbi.nlm.nih.gov/pubmed/21092273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-9-301
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados